Stockscreener 앱 받기
54.19
3.31%
1.7755
전일 마감가:
$52.41
열려 있는:
$53.495
하루 거래량:
9.61M
Relative Volume:
0.59
시가총액:
$110.27B
수익:
$48.03B
순이익/손실:
$6.05B
주가수익비율:
18.30
EPS:
2.9615
순현금흐름:
$15.30B
1주 성능:
+4.79%
1개월 성능:
+16.07%
6개월 성능:
+8.83%
1년 성능:
-2.93%
1일 변동 폭
$53.01
$54.28
1주일 범위
$50.33
$54.28
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.16 | 106.69B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,058.15 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
213.96 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.50 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
134.28 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.34 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock? - Finviz
Bristol-Myers Squibb stock rating upgraded to Buy at BofA on pipeline strength - Investing.com
Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions - Markets Financial Content
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More - 24/7 Wall St.
BMY: Bristol-Myers Squibb Upgraded to Buy by B of A Securities | - GuruFocus
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Pitcairn Co. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Checkpoint Inhibitors Market Is Going to Boom |Bristol-Myers Squibb • Merck & Co. - openPR.com
Caldwell Trust Co Makes New $1.70 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum - Yahoo Finance
Bristol-Myers Squibb Shares Gain Momentum from Regulatory Advances - AD HOC NEWS
Buoyed by BMS milestones, Orum moves to build in-house clinical muscle - koreabiomed.com
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Coppell Advisory Solutions LLC Makes New $1.90 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Birchview Capital LP Has $14.97 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by AQR Capital Management LLC - MarketBeat
BMY Stock Rises: Analyst Upgrade to Buy & Opdivo FDA Priority Review | Dec 12, 2025News and Statistics - IndexBox
Why Bristol-Myers Squibb (BMY) Stock Is Up Today - Finviz
Bristol Myers Squibb’s Opdivo-Plus-Chemotherapy Regimen for Classical Hodgkin Lymphoma Receives FDA Priority Review - Oncodaily
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street's 2026 Focus - ts2.tech
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum? - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More - Yahoo Finance
Guggenheim Upgrades Bristol-Myers Squibb (BMY) to Buy, Sets New Price Target | BMY Stock News - GuruFocus
Peapack Gladstone Financial Corp Reduces Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications - BioSpace
BNP Paribas Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application - pharmiweb.com
Bristol Myers Squibb (BMY) Seeks FDA Approval for Expanded Opdiv - GuruFocus
Bristol Myers wins FDA priority review for Opdivo (BMY:NYSE) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Featured in Sector Research Coverage - Kalkine Media
Nathan Pennell: Proud of Bristol Myers Squibb Team Presenting at ASH25 - Oncodaily
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma - Yahoo Finance
Bristol-Myers Squibb’s Strategic Moves: A Dual Focus on Shareholder Returns and Oncology Expansion - Ad-hoc-news.de
Bristol Myers (BMY) Declares Increased Quarterly Dividend for 20 - GuruFocus
Bristol Myers Squibb raises quarterly dividend by 1.6% - Investing.com Nigeria
Bristol-Myers Squibb Raises Quarterly Dividend by 1.6% to $0.63 a Share, Payable on Feb. 2, 2026 to Shareholders of Record on Jan. 2, 2026 - marketscreener.com
Bristol Myers Squibb Announces Dividend Increase - marketscreener.com
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) t - GuruFocus
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC - Yahoo
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
HSBC Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Maintains Hold Rating - marketscreener.com
Peering Into Bristol-Myers Squibb Co's Recent Short Interest - Sahm
Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound - Yahoo Finance
BioNTech And Bristol’s Pumitamig Is Encouraging In Triple-Negative Breast Cancer - Citeline News & Insights
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
Bristol Myers Squibb Company $BMY Shares Bought by Investment Management Corp of Ontario - MarketBeat
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.72%
1.91%
자본화:
|
볼륨(24시간):